Nicholas Lydon Net Worth & Insider Trades
Nicholas Lydon Blueprint Medicines Corp
What is Nicholas Lydon's Net Worth?
The current estimated net worth of Blueprint Medicines Corp's Nicholas Lydon is estimated to be about $28.94M . Nicholas Lydon owns about 37,425 units of Blueprint Medicines Corp common stock. In the last 6 years at Blueprint Medicines Corp, Nicholas Lydon has sold an estimated value of $13.83M worth.
What is Nicholas Lydon's Past Insider Trading?
Nicholas Lydon's largest sale order was 70,000 units , worth over $2.8M on March 16, 2017. In total, Nicholas Lydon has made about 20 transactions over 6 years of their time at Blueprint Medicines Corp. Nicholas Lydon usually trades in June, with the busiest year in 2020. The most recent transaction was a sale order of 9,815 units , worth over $913.6K on October 5, 2020.
Nicholas Lydon
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
What is Nicholas Lydon's' Mailing Address?
- Mailing address is Blueprint Medicines Corp. 215 First Street, Suite 340/350 Cambridge MA 02142 MA
Blueprint Medicines Corp Executive Compensation
Name |
Year
|
Salary
|
Total
|
|---|---|---|---|
| Jeffrey W. Albers | 2020 | $645,000 | $6,344,667 |
| Jeffrey W. Albers | 2019 | $590,000 | $9,362,371 |
| Jeffrey W. Albers | 2018 | $541,144 | $9,740,799 |
| Michael Landsittel | 2020 | $379,575 | $2,014,974 |
| Michael Landsittel | 2019 | $345,000 | $1,958,720 |
| Michael Landsittel | 2018 | $281,678 | $1,740,610 |
| Fouad Namouni, M.D. | 2020 | $186,154 | $6,668,732 |
| Fouad Namouni, M.D. | 2019 | - | - |
| Fouad Namouni, M.D. | 2018 | - | - |
| Kathryn Haviland | 2020 | $460,944 | $2,363,556 |
| Kathryn Haviland | 2019 | $431,830 | $3,090,423 |
| Kathryn Haviland | 2018 | $392,589 | $2,601,762 |
| Tracey L. McCain, Esq. | 2020 | $453,301 | $2,346,428 |
| Tracey L. McCain, Esq. | 2019 | $437,972 | $2,900,568 |
| Tracey L. McCain, Esq. | 2018 | $425,216 | $2,647,962 |
| No matching records found | |||
Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837021004557/tmb-20210602xdef14a.htm
What are Blueprint Medicines Corp's Past Insider Trades?
Blueprint Medicines Corp's most recent insider trade came on December 7, 2022 by Jeffrey Albers who sold 20,000 units worth $1M . In the last 7 years, insiders at Blueprint Medicines Corp have sold an estimated value of $173.75M and bought an estimated value of $17.63M worth of shares. Insider trading is most common in March, with the busiest year in 2020. The most active traders at the company are Jeffrey Albers, Kate Haviland, CHIEF EXECUTIVE OFFICER, and Ariel Hurley, PRINCIPAL ACCOUNTING OFFICER .
Blueprint Medicines Corp Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||